For years, one of the quiet truths of rare-disease drug development has been that the math simply doesn’t work. Even as gene therapy, CRISPR, base editing and prime editing race ahead, the economics of treating thousands of ultra-rare, mutation-specific disorders still tilt against most patients. Each pathogenic variant — and there are well over 200,000 of them — presents a problem that must be solved, funded and regulated almost individually.
A new study published this week in Nature is prompting a fresh round of industry speculation about whether that model will hold. In the paper, a team led by David Liu at the Broad Institute describes a genome-editing approach called PERT (Prime Editing-mediated Readthrough of Premature Termination codons) that could, at least conceptually, flip the logic of rare-disease therapy: instead of one therapy per mutation, one edit could be leveraged across many diseases caused by the same underlying error — premature stop (nonsense) mutations.
The idea of “universal” or broad-acting rare-disease therapies has been discussed for years, but this is one of the clearest demonstrations of how it might look in practice.
A single tRNA edit with broad implications
The study focuses on nonsense mutations, which account for an estimated 20–25% of pathogenic variants across inherited diseases. Instead of repairing each gene individually, Liu’s team used PERT to convert a redundant endogenous tRNA gene into a suppressor-tRNA capable of reading through a premature stop signal. Once installed, that tRNA supports translation across multiple genes — a single intervention that could, in principle, restore protein production in dozens of genetically distinct conditions.
In cell models of Batten disease, Tay-Sachs disease, cystic fibrosis and several others, the same engineered tRNA restored substantial levels of enzyme activity. In a mouse model of Hurler syndrome, modest editing rates translated into meaningful physiological rescue. Crucially, the work suggests this edit can be done at the genomic “single-copy” level rather than requiring high-expression payloads, potentially limiting disruption to normal cell processes.
The technology is still early, but the conceptual shift is potentially significant: a genome edit installed once, yet therapeutically relevant across many diseases.
From bespoke fixes to broader platforms
For an industry grappling with the cost and complexity of ultra-rare therapies, the strategic implications are hard to ignore.
One obvious consequence is economic. If one editing composition could support multiple indications, the per-indication regulatory and manufacturing burden drops. Rare-disease drug development has largely been constrained by fragmentation — tiny patient populations, small trial sizes, and bespoke CMC processes for each mutation. A platform that consolidates dozens of programmes into a single editing backbone could make once-uneconomic indications viable.
Companies focused on rare-disease pipelines may also rethink portfolio design. Instead of running many single-gene programmes in parallel, a “class-based” approach — targeting, for example, all TAG nonsense mutations with one reagent — becomes feasible. Success in one indication could rapidly de-risk others, potentially accelerating partnerships and licensing discussions.
And then there is the competitive dimension. Gene-editing companies have long differentiated on precision, efficiency and tissue targeting. A broadly acting suppressor-tRNA strategy like PERT introduces a new axis of competition: scalability. Firms with strong delivery platforms may find themselves better positioned to adapt this concept into clinical-grade products.
Still, major caveats remain
The study also makes clear that scientific elegance does not eliminate practical challenges. Editing efficiencies in vivo remain modest, and long-term safety is untested. The current strategy does not yet solve TAA stop codons, leaving a portion of nonsense mutations uncovered. And while the authors report minimal off-target activity and limited disruption to cellular translation, regulators will likely demand extensive safety datasets before any “one-edit-many-diseases” paradigm moves towards human trials.
Delivery remains the limiting reagent. Installing an engineered tRNA across multiple tissues will require vectors capable of reaching the right cells at therapeutic levels, without sparking toxicity or immune responses. In many ways, the bottlenecks are the same ones facing every gene-editing programme today — only magnified by the ambition of the platform.
What comes next
The paper will not upend the rare-disease market overnight, but it may shift how investors and biotech executives think about long-term strategy. A scalable editing platform that targets a shared genetic mechanism could reshape clinical pipelines, partnership models and — if successful — the economics of treating ultra-rare conditions.
For now, the approach sits at the proof-of-concept stage. But it offers a glimpse of a rare-disease future in which companies don’t chase down hundreds of mutations one by one, and patients with the smallest communities aren’t left waiting indefinitely for a bespoke fix. In an industry defined by incremental progress, that possibility alone feels like a significant step forward.